Three Low-Dose Antihypertensive Agents in a Single Pill after Intracerebral Hemorrhage.
Trident Research Group; Anderson CS, Chow CK, de Silva HA, Senanayake B, Wahab K, Al-Shahi Salman R, Klijn CJM, Martins SO, Espinosa N, Kuhles L, Billot L, Arima H, Carcel C, Wang X, Li Q, Shan S, Shanthakumar M, Nguyen HT, Palliyaguruge D, Peiris J, Ranawaka UK, Bandusena S, Rajendiran T, Wijegunasinghe D, Gunasekera H, Wijeweera I, Dissanayake A, Keshavaraj A, Obiako RO, Akinyemi R, Nasi L, Bazan R, Moro CHC, Battaglini M, Zétola V, Law WC, Chia YK, Cordato D, Grimley R, Dahanayaka A, Liyanagamage S, Fernando N, Rasheed NA, Kakabadze N, Beridze M, Aravinthan M, Sahathevan V, Wijesundara D, Ruwanpathirana P, Wan Zaidi WA, Kherkheulidze T, Fischer U, de Souza AC, Lee TH, Chen C, Pontes-Neto O, Robinson T, Wang J, Naismith SL, Barnett M, Delfino C, You S, Liu F, Delcourt C, Moullaali TJ, Wilkinson T, Watson N, Santo K, Han Q, Souza MA, Jolink WMT, Cristofari AB, Zhou Z, Schreuder FH, Lindley RI, Armenis M, Woodward M, Freed R, Song L, Chalmers J, Rodgers A.
Trident Research Group, et al. Among authors: liu f.
N Engl J Med. 2026 Apr 23;394(16):1571-1582. doi: 10.1056/NEJMoa2515043.
N Engl J Med. 2026.
PMID: 42019018
Clinical Trial.
Secondary outcomes included blood-pressure control, major cardiovascular events, death from cardiovascular causes, and safety. RESULTS: Of 1670 patients who underwent randomization, 833 were assigned to receive the triple pill and 837 to receive placebo. ...The mean …
Secondary outcomes included blood-pressure control, major cardiovascular events, death from cardiovascular causes, and safety. …